From the patient’s perspective; Haemophilia February 12, 2019 There are an estimated 400,000 people worldwide living with haemophilia, with approximately 6,000 sufferers in the UK alone. Haemophilia is an inherited disorder that affects the body’s ability to clot. Usually, when someone cuts themselves, clotting factors and platelets combine to make the blood stickier and stop the bleeding. However, in haemophiliacs, the bleeding episodes last longer due to abnormal clotting, and bruising and spontaneous bleeding can also occur too. The main problem for haemophiliacs is internal bleeding into joints, muscles and soft tissues, which can cause pain and stiffness and ultimately lead to joint damage. To better our understanding of the patient’s perspective when it comes to market research studies, we spoke to someone who recently took part in haemophilia research with GKA. Due to the way the condition is inherited, most sufferers tend to be male – however despite it being an inherited disorder, about a third of new diagnoses have no previous family history. There are two types of haemophilia, with Haemophilia A making up 90% of those affected. It is thought that one boy in every 5,000 suffers from Haemophilia A, whilst one in every 30,000 has Haemophilia B. In Haemophilia A, sufferers are lacking in clotting factor VII, whereas in Haemophilia B they lack clotting factor IX. Although there was a bleak outlook for sufferers in the past, today’s treatment means that haemophiliacs can have a good quality of life thanks to factor replacement therapy which injects the missing clotting factor into the bloodstream. Back to blogs written by GKA